Curriculum Vitae

Susan Jones Kalota, M.D.

6325 E. Tanque Verde Road
Tucson, AZ 85715

2954 N. Campbell Avenue #217
Tucson, AZ 85719

EDUCATION:

1975 - 1980	University of California San Diego – B.S. in Biology
1977 - 1978	Jr. Year Education Abroad Program: Pau & Paris, France
1982 - 1986	Howard University College of Medicine: Washington, D.C.
1986 - 1988	University of California San Diego – Surgery Internship
1988 - 1992	University of California San Diego – Urology Residency
10/1990	Observer at Institute of Urology – London, England

CERTIFICATES and LICENSES:

11/1989	Lasers in Urology Surgery – University of Pennsylvania, PA
1992	Arizona Medical License: 20774
1992	Certification in Extracorporeal Shock Wave Lithotripsy
3/1993	Laparoscopic Urologic Surgery – Loma Linda University, CA
2/1994	Diplomate American Board of Urology – Cert. # 10731
12/2001	Recertification - Diplomate American Board of Urology
2/2013	Recertification - Diplomate American Board of Urology
8/2014	Certification in Female Pelvic Medicine and Reconstructive Surgery (FPM-RS)

HONORS, AWARDS and APPOINTMENTS:

1982 - 1984	Academic Achievement Award for academic excellence at Howard University Medical School
1985	Nomination to AOA Medical Honor Society – V.P. of Gamma Chapter of AOA
1986	American Medical Women's Association – Scholarship Achievement Citation
1986	Department of Surgery honorable mention for scholastic achievement
1986	Department of Medicine honorable mention for scholastic achievement

6325 E. Tanque Verde Road Tucson, AZ 85715
2954 N. Campbell Avenue #217 Tucson, AZ 85719

HONORS, AWARDS and APPOINTMENTS (continued):

1986	Ralph C. Kennedy, M.D. Award for highest score in Psychiatry on National Board Exam
1986	Merck Manual Award for highest scholastic records
1986	Graduated Howard University – College of Medicine, Salutatorian
1995 - 2003	Clinical Assistant Professor, Department of Urology, University of Arizona
1999 – 2001	Medicare Urologic Consultant
2000	Chief of Urology, El Dorado Hospital, Tucson, AZ
1999 – Present	Director of Urodynamics Lab, Tucson Medical Center

EMPLOYMENT:

4/2011- Present	Group Practice General Urology- Urological Associates of Southern Arizona, Tucson, AZ
8/1992 – 04/2011	Private Practice General Urology- Arizona Urologic Specialists, Tucson, AZ
7/1988 – 6/1992	Urology Resident – University of California San Diego
1/1987 – 6/1988	General Surgery Internship & Residency – University of California San Diego
6/1986 – 1/1987	Urology Research –University of California San Diego. Study in vivo urea movement across treated bladder epithelium and in-vitro urinary bladder transport
1983 – 1985	Medical Study Tutor – Anatomy, Microbiology and Pathophysiology
1982	Quality Assurance Specialists: Developed Quality Assurance Instruction Manual for General Dynamics – Los Angeles, CA
1979 – 1981	Research Associate – University of California San Diego. Department of Community Medicine study of nutrition and prenatal risk factors to pregnancy outcome.

Curriculum Vitae

Susan Jones Kalota, M.D.

6325 E. Tanque Verde Road
Tucson, AZ 85715

2954 N. Campbell Avenue #217
Tucson, AZ 85719

CORPORATE BOARD ACTIVITIES:

National Association of Corporate Directors (NACD), Foundation.
Member 2016 – present
Course: Director Professionalism 2016

Catalina Cylinders Incorporated, Santa Ana, California
Board of Directors 2017-present

VOLUNTEER ACTIVITIES:

1979	Volunteer Research – Committee for Undernourished People in San Diego, CA Retrospective study of prenatal health and neurologic status of 4 & 5 year old's.
6/1979 – 9/1979	Volunteer Physician's Aide at Planned Parenthood – Los Angeles, CA
1980 – 1981	Peace Corps Volunteer – Ivory Coast, West Africa. Developed well-baby clinic, started vaccination program, taught nutrition and disease prevention
1981	Volunteer Research – VA Hospital San Diego, CA Study of synthetic Hemoglobin
6/1983 – 9/1983	Volunteer Physician's aide at Center for Woman's Health – Los Angeles, CA
6/1984 – 9/1984	Volunteer Physician's aide at Center for Woman's Health – Los Angeles, CA
1999 – 2016	Jimmie Heuga Center Staff Lecturer on NGB on Patients with MS: Patient Evaluations and Exams
1999 – Present	Tucson Multiple Sclerosis Society Lecturer
2004 - 2011	Volunteer Urologist for Annual Health and Prostate Fair – Sponsored by the Gamma Alpha Boule to Target Black Males At Increased Risk for Prostate Cancer
Aug. 2005	IVU (International Volunteers In Urology) Urologic Evaluations of Women with Vesicovaginal Fistulas and Corrective Surgeries - Jos Plateau, Nigeria Africa
Aug. 2006	IVU (International Volunteers In Urology) Urologic Evaluations of Women with Vesicovaginal Fistulas and Corrective Surgeries - Jos Plateau, Nigeria Africa

6325 E. Tanque Verde Road 2954 N. Campbell Avenue #217
Tucson, AZ 85715 Tucson, AZ 85719

VOLUNTEER ACTIVITIES (continued):

Feb. 2008	IVU (International Volunteers In Urology) Urologic Evaluations of Women with Vesicovaginal Fistulas and Corrective Surgeries - Jos Plateau, Nigeria Africa
Aug. 2009	IVU (International Volunteers In Urology) Urologic Evaluations of Women with Vesicovaginal Fistulas and Corrective Surgeries - Jos Plateau, Nigeria Africa
2009 - Present	Volunteer Lecturer for Spinal Cord Injury Support Group
Sep. 2010	IVU (International Volunteers In Urology) Complex Urologic Surgeries on Women with Vesicovaginal Fistulas - Maputo, Mozambique Africa
Sep. 2010	IVU (International Volunteers In Urology) Urologic Evaluations of Women with Vesicovaginal Fistulas and Corrective Surgeries - Jos Plateau, Maputo Mozambique
April 2011	IVU (International Volunteers In Urology) Urologic Evaluations of Women with Vesicovaginal Fistulas and Corrective Surgeries - Kampala, Uganda, Africa
June 2012	IVU (International Volunteers In Urology) Urologic Evaluations of Women with Vesicovaginal Fistulas and Corrective Surgeries - Kampala, Uganda
Oct. 2013	IVU (International Volunteers In Urology) Urologic Evaluations of Women with Vesicovaginal Fistulas and Corrective Surgeries - Kampala, Uganda
Jan. 2017	IVU (International Volunteers In Urology) Workshop de Cirugia Reconstructiva Uretral/Incontinencia Urinaria - Monterrey, Mexico
Nov. 2017	IVU (International Volunteers In Urology) Female Urology Workshop - Dakar, Senegal
Nov. 2018	IVU (International Volunteers In Urology) Female Urology Workshop – Dakar, Senegal
Nov. 2019	IVU (International Volunteers In Urology) Female Urology Workshop – Dakar, Senegal

Curriculum Vitae

Susan Jones Kalota, M.D.

6325 E. Tanque Verde Road
Tucson, AZ 85715

2954 N. Campbell Avenue #217
Tucson, AZ 85719

PROFESSIONAL BACKGROUND/SOCIETY MEMBERSHIP:

Southern Arizona Urologic Society member 1992 – Present
- President 1994
- Secretary 1993

Arizona Urologic Society member 1992 – Present

Western Section of American Urologic Association member 1992 – Present

American Urologic Association member 1988 – Present
- Health Policy Committee 1999 – 2000

Committee on Women's Issues in Urology 1999 – 2000

Society of Woman in Urology 1992 – Present
- President 1999 – 2000
- President-elect 1998 – 1999
- Board of Directors 1997 – 1998

Tucson Society of Woman Physicians 1993 - Present
- President 2002, 2011
- Founding President 1993 – 1994
- Secretary/Treasurer 1994 – Present
- Board of Directors 1994 – Present

Pima County Medical Society 1992 – Present
- Secretary/Treasurer 2001
- Board of Directors 1999 – 2001
- Board of Directors 1996 – 1998
- Vice President 2016 – 2017
- President 2017-2018

Arizona Medical Association 1999 – Present
- Board of Directors 2017-2019

ArMA Committee on Insurance Reform 1999 – 2000

Scientific Advisory Board for Novasys Medical

IVU Med
- Board of Directors October 2012 – Present
- Treasurer April 2016 – Present

Curriculum Vitae

Susan Jones Kalota, M.D.

6325 E. Tanque Verde Road 2954 N. Campbell Avenue #217
Tucson, AZ 85715 Tucson, AZ 85719

PRESENTATIONS:

Jones, S.M. and Parson, C.L. – Prevention of acrolein-induced bladder injury pentosanpolysulfate. AUA 85th Annual Meeting. New Orleans, LA May 1990.

Jones, S.M. The in's and out's of GU Bleeding, Presented to Southern California Chapter of the American Urologic Association Allied. San Diego, CA September 1991.

Speaker for Pfizer, Bayer and Ortho-McNeil
Alza Pharmaceutical Speaker's Bureau 1999 – 2001

Nurse Practitioners Annual Convention - San Diego, CA 2000

Private Practice Gynecologist on simple cystitis - San Francisco, CA 2000

Multiple Community Presentations for Physicians and Lay Persons

Consortium of Multiple Sclerosis Centers- Atlanta, GA 2009

Gender Specific Concerns in MS: Urologic manifestation of MS In the male patient

Consortium of Multiple Sclerosis Centers- San Antonio, TX 2010

Gender Specific Concerns in MS: Urologic manifestation of MS In the male patient

American Urologic Association Annual meeting 2018, San Francisco, CA: BPH

Symposium Phase 3 Clinical Studies and Biology of Fexapotide Triflutate Office

Injectable for BPH, panel

Society of Urodynamics and Female Pelvic Medicine and Urogenital Reconstruction

(SUFU) Annual Meeting 2018: OAB-Therapeutic Algorithm for Third-line Therapies: When I Use What and Why

RESEARCH EXPERIENCE:

Federal Drug Administration (2004-2008) – Gastroenterology and Urology Devices Panel Member - Center for Devices & Radiological Health (CDRH) Office of Device Evaluation (ODE) Division of Reproductive, Abdominal and Radiological Devices (DRARD) Gastroenterology and Renal Devices Branch (GRDB)

Federal Wide Assurance (FWA) # FWA0028620 (2019)

RESEARCH EXPERIENCE (continued):

Site is Approved as an Institutional Biosafety Committee Site under the NIH Guidelines for Research Involving Recombinant DNA Molecules (2019)

Allergan Pharmaceuticals: A Study Evaluating the Efficacy and Safety of BOTOX® Intravesical

Instillation in Patients with Overactive Bladder and Urinary Incontinence

Stress Incontinence: Study Phase 2 (1998)

Urge Incontinence: Study Phase 3B, 8 patients' enrolled, 27 months long (1999)

Pharmacia & Upjohn Pharmaceuticals: Overactive Bladder Study Phase 3B, 6 patients enrolled/12 weeks long (2001)

Pharmacia & Upjohn Pharmaceuticals: Quality of Life Study for Overactive Bladder Phase 4, 18 patients enrolled 8 weeks long (2001)

Urogenital Symptoms in Post Menopausal Women Study Phase 4 (2001)

AstraZeneca Pharmaceuticals: Phase 3 Jupiter: LDL and C-Reaction Protein, Cholesterol (2004)

Pharmatech: Phase 3 Advanced Prostate Cancer (2004)

Pfizer Pharmaceutical- PPD: Phase 4 Overactive Bladder/Pfizer/PPD with Rapid Trials, (2004)

Sanofi-Synthelabo BPH Registry: 22 patients enrolled (2004)

Watson Pharmaceuticals: Quality of Life Study for Oxytrol in OAB 2004, 33 patients enrolled (2004)

AstraZeneca Pharmaceuticals: Overactive Bladder Phase 3 (2005)

Indevus Pharmaceuticals: Double-Blind and Open-Label Drug for OAB (2005)

Odyssey Pharmaceuticals: Phase 4 Overactive Bladder (2005)

Praecis Pharmaceuticals - INC Research: Prostate Cancer Phase 3 (2005)

Astellas Scientific: Phase 4, OAB pts with Sx's of BPH (2006)

Pfizer Pharmaceutical: Phase 2 Stress Incontinence (2006)

RESEARCH EXPERIENCE (continued):

AMS Pharma: The Prolapse Registry: An Observational Collection of Short- and Long-Term Patient Outcomes Following Use of AMS Surgical Devices for the Repair Of Female Genital Prolapse (2007)

Astellas Scientific: Phase 2, Male subjects with LUTS and BOO (2007)

Nymox Pharmaceutical: Phase2, Benign Prostatic hypertrophy (2007)

Solace Therapeutics: An evaluation of the AttnueX Intravesical System in the Management of Female

Patients with Stress Urinary Incontinence (2007)

Astellas Scientific: 047 Phase III Double Blind Placebo Controlled, OAB Study (2008)

Astellas Scientific: 049 Phase III Double Blind Placebo Controlled, OAB Study (2008)

Pfizer Pharmaceutical A0221046 : 12-Week, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled, Parallel-Group, Multicenter Trial To Evaluate The Efficacy And Safety Of Fesoterodine In Comparison To Tolterodine ER In Patients With Overactive Bladder (2008)

Uroplasty, Inc.: Study of Urgent PC Vs. Sham Effectiveness in Treatment of OAB (2008)

Allergan Pharmaceutical: 191622-095: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study of the Safety and Efficacy of a Single Treatment of BOTOX (Botulinum Toxin A) Purified Neurotoxin Complex Followed by a Treatment With Botox as Applicable in Patients with Idiopathic Overactive Bladder and Urinary Incontinence (2009)

Astellas Scientific: 074 Phase III Double Blind, Parallel Group, Placebo Controlled, OAB Study (2009)

Nymox Pharmaceutical: Phase III Randomized Parallel-Group Placebo Controlled, Double Blind Clinical Evaluation/Treatment of BPH (2009)

Pfizer Pharmaceutical: 13Week Single Arm, Open Label, Multicenter Study to Evaluate Refill Adherence and Satisfaction with Fesoterodine Plus "Your Way" Patient Support Plan" in Patients with Symptoms of OAB (2009)

Pfizer Pharmaceutical A0221049: A 12 Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Trial to Evaluate the Efficacy and Safety of Fesoterodine Flexible Dose Regimen in Vulnerable Elderly Patients with Overactive Bladder (2009)

RESEARCH EXPERIENCE (continued):

Allergan Pharmaceuticals: 191622.096: A Multicenter, Long-Term Follow-up Study of Safety and Efficacy of the Safety and Efficacy of Botox (Botulinum Toxin Type-A) Purified Neurotoxin Complex in Patients with Idiopathic Overactive Bladder and Urinary Incontinence (2010)

Ferring Pharmaceuticals: FE 200486 CS30: A Randomized, Parallel Arm, Open-Label Trial Comparing Degarelix with Goserelin Plus Anti-Androgen Flare Protection (Bicalutamide), in Terms of Prostate Size Reduction in Prostate Cancer Patients of Intermediate-to-High Risk, Who Require Neoadjuvant Hormone Therapy Prior to Radiotherapy (Curative Intent) (2010)

Endo Pharmaceutical: EN3348-303: A Phase 3, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared with Mitomycin C in the Intravesical Treatment of Subjects with BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer (2011)

Ethicon Endo-Surgery: CI-10-0009: Multi-Center, Prospective, Randomized, Double-Blind, Sham-Controlled Clinical Study to Evaluate Safety and Effectiveness of a Transcutaneous, High-frequency, Amplitude-Modulated, Non-Invasive Neuromodulation Device on Urgency Urinary Incontinence in Subjects with Overactive Bladder (OAB) (2011)

Nymox Pharmaceutical: NX02-0017: Phase 3 Multicenter Prospective Randomized Parallel-Group Placebo-Controlled Double-Blind Clinical Evaluation of NX-1207 for the Treatment of BPH (2011)

Pfizer Pharmaceutical A0221047-1109: A 12-Week Randomized, Open-Label, Active-Comparator Period Followed by a 12-Week Safety Extension Period to Evaluate the Safety and Efficacy of Fesoterodine in Subjects Aged 6 to 16 Years and >25 kg with Symptoms of Detrusor Overactivity Associated with Neurological Condition (Neurogenic Detrusor Overactivity) (2011)

Astellas Scientific: 905-UC-050: A Randomized, Double-Blind, Parallel, Placebo-Controlled, Phase 4, Multi-Center Study to Assess Efficacy and Safety of VESIcare (Solifenacin Succinate) to Improve Urinary Continence of Subjects after Robotic Assisted Radical Prostatectomy (2012)

Astellas Scientific 9785-CL-0222: A Randomized, Double-Blind, Phase II, Efficacy and Safety Study of MDV3100 (ASP9785) vs. Bicalutamide in castrate Men with Metastatic Prostate Cancer (2012)

Nymox Pharmaceutical: Phase 2 Multicenter Prospective Open Label 2-Dose Level Clinical Safety and Efficacy Evaluation of Injection of NX-1207 for the Treatment of Low Risk, Localized (T1c) Prostate Cancer (2012)

RESEARCH EXPERIENCE (continued):

Nymox Pharmaceutical: NX02-0020: Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-7 Years Apart (2012)

Nymox Pharmaceutical: NX02-FU032010: Follow-Up Multicenter Blinded Clinical Evaluation of Subjects Treated with NX-1207 or Placebo (2012)

Pfizer Pharmaceutical: A 14 Week Randomized Parallel Group Placebo-Controlled Double-Blind Multi-Center Study Of Fesoterodine 8mg In Overactive Bladder Patients With Sub-Optimal Response To Tolterodine 4mg ER (2012)

Allergan Pharmaceuticals: 191622-125: A Study Evaluating the Efficacy and Safety of BOTOX and Solifenacin in Patients with Overactive Bladder and Urinary Incontinence (2013)

Nymox Pharmaceutical: NX02-0022: Phase 3 Multicenter Prospective Open Label Clinical Safety Evaluation of Re-Injection of NX-1207 for the Treatment of BPH: Two Doses 1-8 Years Apart (2013)

Uroplasty Pharmaceutical: MPQ092006 (ROSE REGISTRY): Real-time Observation of Safety and Effectiveness in the treatment of female stress urinary incontinence (2013)

Astellas Scientific 178-MA-1005 (PILLAR): A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Parallel Group, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects with Overactive Bladder (OAB) (2014)

Solace Therapeutics : CD1001 (SUCCESS TRIAL): Urinary in Continence Control, Efficacy and Safety Study. An Evaluation of the Solace Bladder Control System in the Treatment of Adult Female Subjects with Stress Urinary Incontinence (2014)

Astellas Scientific 178-MA-1001 (PREFER): Phase 4: A Prospective, Double-Blind, Randomized, Two-Period Crossover, Multi-Center Study to Evaluate the Tolerability and Patient Preference Between Myrbetriq and Detrol LA in Subjects with Overactive Bladder (OAB) (2015)

Astellas Scientific178-MA-1006 (PERSPECTIVE): A Prospective, Non-interventional, Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder (OAB) (2015)

Astellas Scientific ONC-MA-1004 (TRUMPET): A Prospective Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) in the United States (2015)

RESEARCH EXPERIENCE (continued):

Allena Pharmaceutical: 0000713-03: A Phase 2, Multicenter, Randomized, Placebo Controlled, Double-Blind Study to Evaluate the Efficacy and Safety of ALLN-177 Treatment Over 28 Days in Patients with Secondary Hyperoxaluria and Kidney Stones (2016)

Aquinox Pharmaceuticals: AQX-1125-301: The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by 14 or 40-Week Extension Periods (2016)

Astellas Scientific: A Phase 4, Double-Blind, Randomized, Placebo-controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men with Overactive Bladder OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) (2016)

Astellas Scientific 178-MA-1008 (PLUS): A Phase 4, Double Blind, Randomized, Placebo-controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men with Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) (2016)

Caldura Medical: SUI Treatment Outcomes with Desara® Sling System* (2016)

Ferring Pharmaceuticals: 000108: (PRONOUNCE): A Multi-Center, Randomized, Assessor-Blind, Controlled Trial Comparing the Occurrence of Major Adverse Cardiovascular Events (MACEs) in Patients with Prostate Cancer and Cardiovascular Disease Receiving Degarelix (GnRH Receptor Antagonist) or Leuprolide (GnRH Receptor Agonist) (2016)

Allena Pharmaceutical: ALLN-177-204: A Pilot Study of Oxalate Absorption in Secondary Hyperoxaluria (2017)

Allergan Pharmaceutical: 1839-201-021 (APOLLO Part 1): A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, single-treatment, 2-stage, Dose-finding Study Evaluating the Efficacy and Safety of BOTOX® Intravesical Instillation in Participants with Overactive Bladder and Urinary Incontinence (2017)

Allergan Pharmaceutical: 1839-201-021 (APOLLO Part 2): A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled, Single-treatment, 2-stage, Dose-finding Study Evaluating the Efficacy and Safety of BOTOX® Intravesical Instillation in Participants with Overactive Bladder and Urinary Incontinence (2017)

RESEARCH EXPERIENCE (continued):

Allergan Pharmaceutical:CMO-US-URO-0470 (Lo-BOT): Phase 4 - A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate an Alternative Injection Paradigm for OnabotulinumtoxinA (BOTOX®) in the Treatment of Overactive Bladder in Patients with Urinary Incontinence (2017)

GTx, Inc. (GTx-024): Double-Blind, Placebo-Controlled, Parallel Design, Phase 2 Study to Assess Clinical Activity and Safety of Enobosarm (GTx-024) in Postmenopausal Women With Stress Urinary Incontinence (2017)

Ipsen Pharmaceutical: D-FR-52120-222 (DYSPORT): A phase III, multicentre, randomised, double blind, parallel group, placebo controlled study to assess the efficacy and safety of one or more intradetrusor treatments of 600 or 800 units of Dysport® for the treatment of urinary incontinence in subjects with neurogenic detrusor overactivity due to spinal cord injury or multiple sclerosis (2017)

Nymox Pharmaceutical: NX02-FU02216: Safety Follow-up for Protocols NX02-0020 and NX02-0022 (2017)

Velicept Therapeutics: VEL-2001: A Phase 2b, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Oral Solabegron Modified Release Tablets in the Treatment of Overactive Bladder (OAB) in Adult Female Subjects (2018)

Transition Therapeutics Ireland, Ltd.: SAR-202: A Randomized, Double-blind, Placebo-controlled Dose-ranging Study of OPK-88004 Once-a-day Dosing for 16 Weeks in Men with Signs and Symptoms of Benign Prostatic Hyperplasia (2018)

Anchiano Therapeutics: BC-819-18-204 (CODEX): A Phase 2 Study of BC-819 in Patients with Non-Muscle Invasive Bladder Cancer Whose Disease is Unresponsive to Bacillus Calmette-Guerin (2019)

Allena Pharmaceutical: ALLN-177-301: Evaluate the Safety and Efficacy of ALLN-177 in Patients with Enteric Hyperoxaluria: A Phase III Randomized, Placebo-Controlled Study (2019)

Allena Pharmaceutical: ALLN-177-302 (URIROX-2) (2019): Establishing the Safety and Efficacy of Reloxaliase (Oxalate Decarboxylase) in Patients with Enteric Hyperoxaluria: A Phase III , Randomized, Double-Blind, Placebo-Controlled Study (2019)

GlaxoSmithKline Pharmaceutical: 2017N318043-00: A Phase III, Randomized, Multicenter, Parallel-Group, Double-Blind, Double-Dummy Study in Adolescent and Adult female Participants Comparing the Efficacy and Safety of Gepotidacin to Nitrofurantoin in the Treatment of Uncomplicated Urinary Tract Infection (Acute Cystitis) (2019)

6325 E. Tanque Verde Road 2954 N. Campbell Avenue #217
Tucson, AZ 85715 Tucson, AZ 85719

RESEARCH EXPERIENCE (continued):

Urovant Sciences: URO-901-3005: A Phase 3 Double-Blind, Randomized, Placebo-Controlled, Multi-Center Study to Evaluate the Efficacy, Safety and Tolerability of Vibegron in Men with Overactive Bladder (OAB) Symptoms on Pharmacological Therapy for Benign Prostatic Hyperplasia (BPH) (2019)

PUBLISHED WORK:

Parsons, C.L., Boychuk, D., Jones, S.M., Hurst, R. and Callahan, H. – Bladder surface glycosaminoglycans: an epithelialpermeability barrier. JUrol 143: 139-142 1990.

Jones, S.M., Parsons, C.L. and Stein, P. – Prevention of acrolein inducted bladder injury by pentosanpolysulfate, JUrol 143(4): 280A 1990.

Jones, S.M., Stein, P.C. and Parsons, C.L. - Prevention of acrolein inducted bladder injury by pentosanpolysulfate, JUrol 148(1) 163 – 166 1990.

Jones, S.M. – The Injured Bladder AUA Today.

Jones, S.M., Greene, L.F. and Parsons, C.L. – Evaluation of the urologic patient. The Practice of Urology W.W. Norton & Co. New York, NY 1992

Bidar, M., Kalota, S.M. and Kaplan, G.W. – Infantile hypertrophic pyloric stenosis and hydronephrosis: Is there an association? JUrol 150(1) 153-155.

Stratasis Small Intestinal Submucosa Tension-Free Sling Case Report JUro 172(4): 1349 – 1350 October 2004.

Susan Jones Kalota, M.D.

Nov 18, 2019
Date